Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
about
Targeted therapies in sarcomas: challenging the challengeHepatic falciform ligament clear cell myomelanocytic tumor: A case report and a comprehensive review of the literature on perivascular epithelioid cell tumorsMalignant perivascular epithelioid cell tumor (PEComa) of the femur: a case report and literature reviewActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Response and acquired resistance to everolimus in anaplastic thyroid cancerTreatment of Adult Soft Tissue Sarcomas: An OverviewHigh-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingThe evolution of systemic therapy in sarcoma.Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.mTORC1 activation in childhood ependymoma and response to sirolimus.Malignant PEComa: a case report with emphasis on clinical and morphological criteria.Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition.A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.New therapeutic targets in soft tissue sarcoma.Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat modelMalignant perivascular epithelioid cell tumor (PEComa) of cervix with TFE3 gene rearrangement: a case report.Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.Perivascular epithelioid cell neoplasm of the uterine cervix: an unusual tumor in an unusual location.Emerging therapies for adult soft tissue sarcoma.Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.The off-label use of targeted therapies in sarcomas: the OUTC'S programPancreatic perivascular epithelioid cell tumour presenting with upper gastrointestinal bleeding.PEComa in a Young Patient with Known Li-Fraumeni Syndrome.A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report.Dichotomy of Genetic Abnormalities in PEComas With Therapeutic ImplicationsA phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Targeted therapy in sarcomas other than GIST tumorsPrimary malignant gastric PEComa - Diagnostic and technical dilemmasMalignant perivascular epithelioid cell tumor arising in the mesentery: A case reportThe role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor"Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.Pancreatic perivascular epithelioid cell tumor: A case report with clinicopathological features and a literature review.Advances in sarcoma genomics and new therapeutic targets.Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approachesCytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.Lymphangioleiomyomatosis - a wolf in sheep's clothing.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Multimodality therapy for metastatic sarcomas confined to the lung.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.
P2860
Q21285014-78C2FF46-7280-4326-B38A-455CCC9B3C9EQ26772169-B3DD2551-4992-475E-80CF-4E44AD9A855AQ27030897-2533C23D-CAD5-4093-B049-3A1E66A1384AQ27852954-E01275BD-E2E4-44A0-87DB-3A79515CE7F7Q27853080-0D542B76-9EE3-4496-9F3B-DBAB5BD33F30Q28088685-0CEF0DFB-D6C8-418C-828C-9EC334BA578DQ30514084-82DFF586-CB82-4BAE-9DE9-3DE5343D7B4CQ33274710-F4B476FD-5908-4D31-926E-2E7F221550EEQ33416342-20BCE1AC-17FA-4208-B854-CD92A979E10EQ33746501-DC0B6FA4-8FFA-4307-BD20-6B7400BA00A4Q33805499-1E95BA36-CB1A-4C10-BAB0-D00BE8BAC86EQ33841595-B0979AD5-0FD9-474A-ACEA-95E793A66894Q33977969-15D2D4E2-6F7C-4812-AC96-C8C3AD472FF2Q34267924-FEE14170-861B-487D-9BDD-58C3EFBE777EQ34325616-8CD17FA1-0C7E-49AA-B224-448ED4D8A69EQ34371874-CDCE869D-9F51-48F2-87FE-5BC5BA2EA62CQ34450447-107467E8-ED1D-480D-9C23-7BBD39B401BBQ34483290-D4847429-5D28-4189-874B-F112D90D7E5FQ34659806-F8E665D2-CB39-4637-8A69-A4C441AD66C7Q34664479-7F418819-3DED-420B-AD31-452DD7567933Q34795914-B437DF8A-BB8B-4D2B-A356-04078E831EA3Q34897996-C0782BF7-26FC-437A-A4E5-FB20DEC202CFQ34997300-1C0968C3-E446-4095-858C-48E81773B904Q35189626-59495C53-559E-4E40-B84C-29121E439287Q35203838-7AD7744E-6CF1-4F85-A8AB-8FF6E3411C58Q35606985-D27D3E1B-AC3D-4978-9CF0-0638F722130EQ35616803-3FBB4F5B-DD51-48A9-A44D-E81EBEFAC986Q35622367-2B8B7F17-F988-4478-9881-EB15C142DC00Q35701882-6126E8F2-B154-4C9F-B3F6-0569457F4350Q35742194-DDCFC53F-CE9A-4F98-979B-A1257D4BBAA8Q35918797-BD57CB89-5E96-4426-8503-134DF5F4587CQ35955322-5768A702-F05F-4F65-98E4-40D832974E9EQ35982066-BE433114-CB0C-4375-9C5E-23AF8EF80428Q35993346-E17A36E9-D497-467A-AFE1-8A1613565CFDQ36144210-F69D70D1-D956-4782-9FC0-7FD51A008984Q36190182-D06C43C2-6B1C-40A3-ABC1-DB72BAEAE0E8Q36357766-FFEC839D-1476-4ED7-9994-EB84CEE319FCQ36389964-E2E70E0F-F5B5-479A-96AF-67999BB05F16Q36424138-2CDBD776-746F-46DB-B3E1-E9E2170C253BQ36444369-F6AF4C4C-DA67-434D-97D4-37D19F66BCD1
P2860
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@ast
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@en
type
label
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@ast
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@en
prefLabel
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@ast
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@en
P2093
P2860
P356
P1476
Clinical activity of mTOR inhi ...... ctivation of mTORC1 in tumors.
@en
P2093
Andrew J Wagner
Azra H Ligon
Christopher D M Fletcher
Cristina R Antonescu
David J Kwiatkowski
George D Demetri
Izabela Malinowska-Kolodziej
Jeffrey A Morgan
Natalie Vena
Nikhil H Ramaiya
P2860
P304
P356
10.1200/JCO.2009.25.2981
P407
P577
2010-01-04T00:00:00Z